Csorba, Kinga; Schirmbeck, Lucia A; Tuncer, Eylul; Ribi, Camillo; Roux-Lombard, Pascale; Chizzolini, Carlo; Huynh-Do, Uyen; Vanhecke, Dominique; Trendelenburg, Marten (2019). Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site. Frontiers in immunology, 10, p. 2619. Frontiers Research Foundation 10.3389/fimmu.2019.02619
|
Text
fimmu-10-02619.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
Previous infection with Epstein-Barr virus (EBV) is believed to trigger autoimmunity and to drive autoantibody generation as occurring in patients with systemic lupus erythematosus (SLE). Complement C1q and autoantibodies targeting it (anti-C1q) are also considered to be involved in the pathogenesis of SLE, independently of the impact of environmental insults. Still, the circumstances under which these autoantibodies arise remain elusive. By studying a major antigenic site of C1q targeted by anti-C1q (A08), we aimed to determine environmental factors and possible mechanisms leading to the development of anti-C1q. First, we determined antigenic residues of A08 that were critical for the binding of anti-C1q; importantly, we found the binding to depend on amino-acid-identity. Anti-C1q of SLE patients targeting these critical antigenic residues specifically cross-reacted with the EBV-related EBNA-1 (Epstein-Barr virus nuclear antigen 1)-derived peptide EBNA348. In a cohort of 180 SLE patients we confirmed that patients that were seropositive for EBV and recognized the EBNA348 peptide had increased levels of anti-A08 and anti-C1q, respectively. The correlation of anti-EBNA348 with anti-A08 levels was stronger in SLE patients than in matched healthy controls. Finally, EBNA348 peptide-immunization of C1q-/- mice induced the generation of cross-reactive antibodies which recognized both the A08 epitope of C1q and intact C1q. These findings suggest that anti-C1q in SLE patients could be induced by an EBV-derived epitope through molecular mimicry, thereby further supporting the pathogenic role of EBV in the development of SLE. Considering the role of C1q and anti-C1q, modifying the anti-EBV response might be a promising strategy to improve the course of the disease.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension |
UniBE Contributor: |
Huynh-Do, Uyen |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1664-3224 |
Publisher: |
Frontiers Research Foundation |
Language: |
English |
Submitter: |
Uyen Huynh-Do |
Date Deposited: |
05 May 2020 17:20 |
Last Modified: |
05 Dec 2022 15:38 |
Publisher DOI: |
10.3389/fimmu.2019.02619 |
PubMed ID: |
31787984 |
Uncontrolled Keywords: |
A08 epitope C1q deficient mice EBNA-1 Epstein-Barr virus anti-C1q antibody autoimmunity molecular mimicry systemic lupus erythematosus |
BORIS DOI: |
10.7892/boris.143656 |
URI: |
https://boris.unibe.ch/id/eprint/143656 |